-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Unicycive Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2020 to Q2 2024.
- Unicycive Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$7.4M, a 71.2% decline year-over-year.
- Unicycive Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$28.9M, a 48.7% decline year-over-year.
- Unicycive Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$20.8M, a 15.1% decline from 2022.
- Unicycive Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$18.1M, a 101% decline from 2021.
- Unicycive Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$8.98M, a 344% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)